Last reviewed · How we verify

NCT04377880: ROSA

Development of Cellular Models for Osteoblast Response Study to Adipocytic Secretions in an Osteoporosis Context.

Completed Last updated 23 December 2025
What this trial tests

trial in Osteoporosis in 20 participants. Completed in 4 September 2024.

Timeline
15 October 2020
Primary endpoint
4 September 2024
4 September 2024

Quick facts

Lead sponsorUniversity Hospital, Lille
StatusCompleted
Study typeOBSERVATIONAL
Enrollment20
Start date15 October 2020
Primary completion4 September 2024
Estimated completion4 September 2024
Sites1 location across France

Conditions studied

Sponsor

University Hospital, Lille

Who can join

18 and older, any sex, with Osteoporosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The recent studies suggest that secretions from medullary adipocytes are involved in the mechanisms of bone loss in osteoporosis (OP) through their actions on neighbouring osteoforming cells, the osteoblasts. The objective of the research is the development of new cellular models representing the aging skeleton to confirm this hypothesis. To this end, osteoblasts will be isolated from human bone fragments coming from femoral heads discarded during total hip replacement surgery. The osteoblastic response to secreted factors released from medullary adipocytes of commercial origin will be analysed using conditioned media incubations. This phenotypic response will be quantified for each subject through the analysis of gene expression levels. Inter-subject phenotype variations will be related to bone density and microarchitecture data obtained by X-ray microtomography. This will assess the existence of a correlation between the osteoblast response to adipocyte secretions and the degree of osteoporosis of the subject from whom the cells are derived.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Adipose tissue in bone regeneration - stem cell source and beyond.
    Labusca L. · · 2022 · cited 9× · PMID 35949397 · DOI 10.4252/wjsc.v14.i6.372

Verify or expand the search:

Other recruiting trials for Osteoporosis

Currently open trials in the same condition.

Other University Hospital, Lille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04377880.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing